Articles related to CLONAL HEMATOPOIESIS (CH)

The occurrence of second tumors, such as T-cell lymphomas, post-CAR T-cell therapy is rare. The study identifies Epstein-Barr virus and mutant clonal hematopoiesis as potential factors but finds no evidence of oncogenic retroviral integration, providing valuable insights for clinical practice.

Discover how the new Clonal Hematopoiesis Risk Score can help predict myeloid neoplasm risk in CHIP/CCUS patients.

Explore the intricate relationship between stem cell self-renewal and precancer states to better understand its implications for future cancer therapies

The surprising association between CHIP and a lowered risk of Alzheimer’s disease offers a novel perspective in our understanding of neurodegenerative disorders and paves the way for potential future therapeutics.

Responses to conventional donor lymphocyte infusion for post-allogeneic hematopoietic cell transplantation relapse are typically poor. Natural killer cell-based therapy is a promising modality to treat post-HCT relapse. This ongoing phase I trial of adoptively transferred cytokine induced memory-like (CIML) NK cells in patients with myeloid malignancies relapsed after haploidentical HCT saw a dynamic evolution of the activated CIML NK cell phenotype, superimposed on the natural variation in donor NK cell repertoires.

The authors analyzed the outcome of 349 patients with primary or secondary myelofibrosis undergoing reduced intensity transplantation, of whom 35 had accelerated-phase myelofibrosis. After a median follow-up of 5.9 years, estimated 5-year overall survival was between the two groups, and median overall survival was not reached. In terms of relapse, five-year incidence was 30% for the accelerated-phase group versus 15% for the chronic-phase group. Reduced intensity transplantation showed excellent survival but higher relapse for accelerated-phase myelofibrosis.